Stock LBPH LONGBOARD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
21.96 USD +3.10% Intraday chart for Longboard Pharmaceuticals, Inc. +11.19% +264.18%
01/05 Baird Starts Longboard Pharmaceuticals With Outperform Rating, $36 Price Target MT
26/03 Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Baird Starts Longboard Pharmaceuticals With Outperform Rating, $36 Price Target
MT
LONGBOARD PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
BU
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding
CI
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index
CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
BU
LONGBOARD PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
BU
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating
MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating
MT
LONGBOARD PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE OF UNDERWRITERS OPTION TO PURCHASE ADDITIONAL SHARES
AQ
Longboard Pharmaceuticals Closes $242 Million Public Offering
MT
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BU
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating
MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating
MT
Longboard Pharmaceuticals Prices $210 Million Stock Offering
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LBPH Stock
  4. News Longboard Pharmaceuticals, Inc.